Phosphodiesterase inhibitors: History of pharmacology

Handbook of Experimental Pharmacology

Volumn 204, Issue , 2011, Pages 1-46

  Schudt, Christian ^a   Hatzelmann, Armin ^a   Beume, Rolf ^a   Tenor, Hermann ^a  

^a Nycomed GmbH   (Germany)

Author keywords

Asthma; COPD; PDE inhibitors; PDE4 inhibitors

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4,5 DIHYDRO 6 [4 (1H IMIDAZOL 1 YL)PHENYL] 5 METHYL 3(2H) PYRIDAZINONE; 5 (4 ACETAMIDOPHENYL) 2(1H) PYRAZINONE; AMINOPHYLLINE; AMRINONE; BENAFENTRINE; CARDIAC GLYCOSIDE; CILOMILAST; CILOSTAZOL; DENBUFYLLINE; ENOXIMONE; ISOPRENALINE; MILRINONE; MOTAPIZONE; NITRIC OXIDE; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROFLUMILAST; ROLIPRAM; SIGUAZODAN; SILDENAFIL; THEOBROMINE; THEOPHYLLINE; XANTHINE DERIVATIVE; ZAPRINAST; ZARDAVERINE; BRONCHODILATING AGENT;

ANTIINFLAMMATORY ACTIVITY; ASCITES; ASTHMA; BASOPHIL; BRONCHODILATATION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLUMN CHROMATOGRAPHY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG ISOLATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; DYSPNEA; ENZYME INHIBITION; EOSINOPHIL; ERECTILE DYSFUNCTION; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART PALPITATION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; INFLAMMATION; INTERMITTENT CLAUDICATION; LEG EDEMA; LOW DRUG DOSE; LUNG EDEMA; MACROPHAGE; MONOCYTE; MULTIINFARCT DEMENTIA; NAUSEA AND VOMITING; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE RELAXATION; T LYMPHOCYTE; TACHYCARDIA; THROMBOCYTE AGGREGATION INHIBITION; TREMOR; UNSPECIFIED SIDE EFFECT; ANIMAL; PHYSIOLOGY;

ANIMALS; ASTHMA; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THEOPHYLLINE;

EID: 79960901315     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-17969-3_1     Document Type: Review

References (212)

1. Allard E (1904) Über Theocinvergiftung. Arch Klin Med 80:510-519
2. Alousi AA, Farah AE, Lesher GY, Opalka CJ (1979) Cardiotonic activity of amrinone-Win 40680 [5-amino-3, 4′-bipyridine-6(1H)-one]. Circ Res 45:666-677 (Pubitemid 10195657)
3. American Thoracic Society (1962) Definitions and classifications of chronic bronchitis, asthma and pulmonary emphysema. Am Rev Respir Dis 85:762-768
4. Andersson P (1980) Antigen-induced brochial anaphylaxis in actively sensitized guinea pigs. Allergy 35:65-71
5. Au BT, Teixeira MM, Collins PD, Williams TJ (1998) Effect of PDE4 inhibitors on zymosaninduced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br J Pharmacol 123:1260-1266 (Pubitemid 28120527)
6. Barnes PJ (1998) New therapies for chronic obstructive pulmonary disease. Thorax 53:137-147 (Pubitemid 28212141)
7. Barnes PJ (2003a) Theophylline, new perspectives of an old drug. Am J Respir Crit Care Med 167:813-818 (Pubitemid 36801766)
8. Barnes PJ (2003b) New concepts in chronic obstructive pulmonary disease. Annu Rev Med 54:113-129 (Pubitemid 37386387)
9. Barnes PJ, Celli B (2008) Systemic manifestations and comorbidities of COPD. Eur Respir J 33:1665-1685
10. Barnes PJ, Rennard SI (2008) Pathophysiology of COPD. In: Barnes PJ, Drazen J, Rennard SI, Thomson N (eds) Asthma and COPD. Basic mechanisms and clinical management. Academic, Amsterdam, pp 425-442
11. Barnes AP, Livera G, Huang P, Sun C, ONeal WK, Conti M, Stutts MJ, Milgram SL (2005) Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J Biol Chem 280:7997-8003 (Pubitemid 40349697)
12. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, Torphy TJ (1995a) Inhibitors of phosphodiesterase IV (PDEIV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273:1396-1402
13. Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ (1995b) The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J Pharmacol Exp Ther 273:674-679
14. Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, Torphy TJ (1996) Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H] rolipram binding. Biochem Pharmacol 51:949-956 (Pubitemid 26111151)
15. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, Torphy TS (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284:420-426 (Pubitemid 28109574)
16. Beavo JA (1988) Multiple isozymes of cyclic nucleotide phosphodisterase. Adv Sec Messengers Phosphoprotein Res 22:1-38
17. Beavo JA, Conti M, Heaslip RJ (1994) Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46:399-405 (Pubitemid 24296671)
18. Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi A (1978) Hemodynamic assessment of amrinone. N Engl J Med 299:1373-1377
19. Beume R, Kilian U, Brand U, Hafner D, Eltze M, Flockerzi D (1993) The bronchospasmolytic effects of the PDEIII/IV inhibitors B9004-70 and zardaverine -dependency on the route of administration in guinea pigs. Am Rev Respir Dis 174:A184
20. Boero S, Silvestri M, Sabatini F, Nachira A, Rossi GA (2006) Inhibition of human lung fibroblast functions by roflumilast N-oxide. Eur J Respir (Suppl) 662s:P3845, abstract
21. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52
22. Brindley GS (1982) Intracavernous injection of papaverine for erectile failure. Lancet 2:938
23. Brindley GS (1986) Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 87:495-500 (Pubitemid 17178767)
24. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001) In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297:280-290 (Pubitemid 32242588)
25. Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28:63-70
26. Burkman AM (1982) Assessment of emetic and antiemetic activity. J Pharmacol Meth 8:165-171
27. Butcher RW (1984) Phosphodiesterase after 20 years: an Introduction. Adv Cycl Nucl Protein Phos Res 16:1-12
28. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, M2-124 and M2-125 study groups (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease. Two randomized clinical trials. Lancet 374:685-94
29. Campbell SF (2000) Science, art and drug discovery: a personal perspective. Clin Sci 99:255-260
30. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, Zielenski J, Durie P (2006) Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 173:1139-44 (Pubitemid 43726895)
31. Cervin A, Lindgren S (1998) The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro. Auris Nasus Larynx 25:269-76 (Pubitemid 28440587)
32. Chikanza IC, Jawed SJ, Blake DR, Perrot S, Menkes CI, Barnes CG, Perry JD, Wright MG (1996) Treatment of patients with rheumathoid arthritis with RP73401 phosphodiesterase type IV inhibitor. Arthritis Rheum 39:282
33. Christensen SB, DeWolf WE, Ryan MD, Torphy TJ (1996) Molecular aspects of inhibitor interaction with PDE4. In: Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors. Acedemic, London
34. Churg A, Cosio M, Wright JL (2008) Mechanism of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol 294:L612-L631 (Pubitemid 351520094)
35. Cockroft DW (1983) Mechanism of perennial allergic asthma. Lancet 322:253-256
36. Cohen NA, Zhang S, Sharp DB, Tamashiro E, Chen B, Sorscher EJ, Woodworth BA (2009) Cigarette smoke condensate inhibits transepithelial chloride transport and ciliary beat frequency. Laryngoscope 119:2269-2274
37. Compton CH, Gubb J, Nieman R, Edelson J, Ohad A, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC (2001) Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358:265-270 (Pubitemid 32738964)
38. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
39. Cortijo J, Bou J, Cardelus I, Llenas J, Morcillo E, Gristwood RW (1993) Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol 108:562-568 (Pubitemid 23032571)
40. Cortijo J, Iranzo A, Milara X, Mata M, Cerdá-Nicolás M, Ruiz-Saur?́ A, Tenor H, Hatzelmann A, Morcillo EJ (2009) Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol 156:534-544
41. Coyle AJ, Urwin SJ, Page CP, Touvay C, Villain B, Braquet P (1988) The effect of selective PAF antagonist BN52021 on PAF-and antigen-induced bronchial hyper-reactivity and eosinophil accumulation. Eur J Pharmacol 148:51-58 (Pubitemid 18082017)
42. Cushley MJ, Holgate ST (1985) Adenosine-induced bronchoconstriction in asthma: role of mast cell-mediator release. J Allergy Clin Immunol 75:272-278 (Pubitemid 15239081)
43. Dent G, Rabe KF, Giembycz MA (1990) Inhibition of eosinophil respiratory burst activity by type IV-but not by type III-selective phosphodiesterase inhibitors. A Rev Respir Dis 141:A878
44. Dent G, Giembycz MA, Rabe KF, Barnes PJ (1991) Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by "type IV"-selective PDE inhibitors. Br J Pharmacol 103:1339-1346
45. Dent G, White SR, Tenor H, Bodtke K, Schudt C, Leff AR, Magnussen H, Rabe KF (1998) Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther 11:47-56 (Pubitemid 28510719)
46. Diebold I, Djordjevic T, Petry A, Hatzelmann A, Tenor H, Hess J, Gorlach A (2009) Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2. Circ Res 104:1169-77
47. Dunkern T, Hatzelmann A (2005) The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal 17:331-339 (Pubitemid 39574694)
48. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A (2007) Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572:12-22 (Pubitemid 47374681)
49. Engelstaetter R, Wingertzahn M, Schmid-Wirlitsch C, Bredenbroker D, Leichtl S, Wurst W (2005) Roflumilast, an investigational, oral, once daily phosphodiesterase 4 inhibitor, did not exhibit acute bronchodilatory activity after a single dose. Ann Allergy Asthma Immunol 94:169
50. England PJ, Shahid M (1987) Effects of forskolin on contractile responses and protein phosphorylation in the isolated perfused heart. Br J Pharmacol 264:687-695 (Pubitemid 17127021)
51. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF (2009) M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 374:695-703
52. Farah AE, Alousi AA (1978) New cardiotonic agents: a search for digitalis substitute. Life sci 22:1139-1148 (Pubitemid 8339707)
53. Filley GF (1967) Emphysema and chronic bronchitis: clinical manifestations and their physiologic significance. Med Clin North Am 51:283-292
54. Fischer E, Ach L (1895) Synthese des Caffeins. Berichte der deutschen Gesellschaft 28:3135
55. Fischer W, Schudt C, Wendel A (1993) Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice. Biochem Pharmacol 12:2399-2404 (Pubitemid 23189531)
56. Fitzgerald MF, Spicer D, Henning R (2003) Efficacy of the PDE4 inhibitor Bay 19-8004 and a steroid in tobacco smoke-induced models of pulmonary inflammation in the mouse. Am J Respir Crit Care Med 167:A91
57. Fitzgerald MF, Spicer D, McAulay AE, Wollin L, Beume R (2006) Roflumilast but not methylprednisolone inhibited cigarette smoke-induced pulmonary inflammation in guinea pigs. Eur Respir J Suppl 663s:P3850, abstract
58. Foster RW, Rakshi K, Carpenter JR, Small RC (1992) Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volonteers during methacholine challenge test. Br J Clin Pharmacol 34:527-534
59. Francis SH, Lincoln TM, Corbin JD (1980) Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 255:620-626 (Pubitemid 10112364)
60. Frossard N, Landry Y, Pauli G, Ruckstuhl M (1981) Effects of cyclic AMP-and cyclic GMP-phosphodiesterase inhibitors on immunological release of histamine and lung contraction. Br J Pharmacol 73:933-938 (Pubitemid 11033780)
61. Fuhrmann M, Jahn HU, Seybold J, Neurohr C, Barnes PJ, Hippenstiel S, Kraemer HJ, Suttorp N (1999) Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 20:292-302 (Pubitemid 129504890)
62. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A (1997a) In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-a release by PDE inhibitors. Br J Pharmacol 121:221-231 (Pubitemid 27192708)
63. Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A (1997b) Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 100:527-537
64. Gantner F, Schudt C, Wendel A, Hatzelmann A (1999) Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC functions. Pulm Pharmacol Ther 12:377-386 (Pubitemid 30015810)
65. Ghofrani HA, Wiedemann R, Rose F, Olschewki H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002a) Combination therapy with oral sildenafil and inhaled ileprost for severe pulmonary hypertension. Ann Intern Med 136:515-522 (Pubitemid 34252285)
66. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F (2002b) Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 30:2489-2492 (Pubitemid 35351868)
67. Ghofrani HA, Osterloh IH, Grimminger F (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Rev 5:689-702 (Pubitemid 44151606)
68. Giembycz MA, Field KF (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Dev Ther 4:147-158
69. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PF (1996) Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118:1945-1958 (Pubitemid 26292562)
70. Goldie RG, Papadimitriou JM, Paterson JW, Rigby PJ, Self HM, Spina D (1986) Influence of the epithelium on responsiveness of guinea-pig isolated trachea to contractile and relaxant agonists. Br J Pharmacol 87:5-14 (Pubitemid 16165886)
71. Greene JA, Paul WD (1937) The action of theophylline with ethylenediamine on intrathecal and venous pressure in cardiac failure and on bronchial obstruction in cardiac failure an bronchial asthma. J Am Med Assoc 109:1712
72. Grimminger F, Spriesterbach R, Weissmann N, Walmrath D, Seeger W (1995) Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol 78:1509-1515
73. Grootendorst DC, Gauw SA, Baan R, Kelly J, Murdoch RD, Sterk PJ, Rabe KF (2003) Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast/15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? Pulm Pharmacol Ther 16:115-129
74. Grueter R (1910) Über leicht losliche Verbindungen des Theophyllins. Therapeutische Monatshefte 24:613
75. Hamilton TC (1972) The effects of some phosphodiesterase inhibitors on the conductance of the perfused vascular beds of the chloralosed cat. Br J Pharmacol 46:386-394
76. Hannon JP, Tigani B, Williams I, Mazzoni L, Fozard JR (2001) Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats. Br J Pharmacol 132:1509-1523 (Pubitemid 32281040)
77. Hargreave FE (1989) Late-phase asthmatic responses and airway inflammation. J Allergy Clin Immunol 83:525-527 (Pubitemid 19087922)
78. Harris AL, Conell MJ, Ferguson EW, Wallace AM, Gordon RJ, Pagani ED, Silver PJ (1989) Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther 251:199-206
79. Hatzelmann A, Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279 (Pubitemid 32242587)
80. Hatzelmann A, Tenor H, Schudt C (1995) Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 114:821-831
81. Hatzelmann A, Engelstatter R, Morley J, Mazzoni L (1996a) Enzymatic and functional aspects of dual-selective PDE3/4 inhibitors. In: Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors. Academic, London
82. Hatzelmann A, Haefner D, Beume R, Schudt C (1996b) Automatic leukocyte differentiation in bronchoalveolar lavage fluid of guinea pigs ad Brown-Norway rats. J Pharmacol Toxicol Meth 35:91-99 (Pubitemid 26121380)
83. Hatzelmann A, Morcillo E, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H (2010) The preclinical pharmacology of roflumilast -a selective, oral phosphodiesterase inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23(4):235-256
84. Hedqvist P, Fredholm BB, Olundh S (1978) Antagonistic effects of theophylline and adenosine on adrenergic neuroeffector transmission in the rabbit kidney. Circ Res 43:592-598 (Pubitemid 9022303)
85. Hermann GR, Aynesworth MB, Martin J (1937) Successful treatment of persistent extreme dyspnea, "status asthmaticus" -use of theophylline ethylene diamine (aminophylline, U.S.P.) intravenously. J Lab Clin Med 23:135
86. Hidaka H, Asano T (1976) Human platelet 30:50-cyclic nucleotide phosphodiesterase. Biochem Biophys Acta 429:485-497
87. Hirsch S (1922) Klinischer und experimenteller Beitrag zur krampflosenden Wirkung der Purinderivate. Klinische Wochenschrift 1:615-618
88. Holden CA, Chan SC, Hanifin JM (1986) Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J Invest Dermatol 87:372-376 (Pubitemid 16051180)
89. Honerjager P, Schafer-Korting M, Reiter M (1981) Involvement of cyclic AMP in direct inotropic action of amrinone. Naunyn-Schmiedebergs Arch Pharmacol 318:112-120
90. Horowski R, Sastre-Hernandez M (1985) Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res 38:23-29
91. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J (1990) Nitric oxide and cyclic GMP formation upon a electric fields stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Comm 170:843-850 (Pubitemid 20249496)
92. Izikki M, Raffestin B, Klar J, Hatzelmann J, Marx D, Tenor H, Zadigue P, Adnot S, Eddahibi S (2009) Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia-and monocrotalineinduced pulmonary hypertension in rats. J Pharmacol Exp Ther 330:54-62
93. Jones NA, Boswell-Smith V, Lever R, Page CP (2005) The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18:93-101 (Pubitemid 40092659)
94. Kaliner M, Orange R, Austen F (1972) Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med 136:556-566
95. Kammer GM (1988) The adenylate cyclise-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 9:222-229
96. Katsuki S, Arnold W, Mittal C, Murad F (1977) Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cycl Nucl Res 3:23-35 (Pubitemid 8078230)
97. Kay AB (1987) Inflammatory cells in acute and chronic asthma. Am Rev Respir Dis 135:S63-66
98. Kilian U, Beume EM, Schudt C (1989) Is phosphodiesterase inhibition a relevant bronchospasmolytic principle? Agents Actions (Suppl) 28:331-348
99. Klar J, Sabatini F, Schatton E, Burgbacher B, Rossi GA, Hatzelmann A, Tenor H (2007) Roflumilast N-oxide reduces human fibroblast function. Eur Respir J (Suppl) 544s:3258, Abstract
100. Kleine-Tebbe J, Wicht L, Gagne H, Friese A, Schunack W, Schudt C, Kunkel G (1992) Inhibition of IgE.mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors. Agents Actions 36:200-206
101. Klotz L (2005) How (not) to communicate scientific information: a memoir of the famous Brindley lecture. Br J Urol 95:956-957 (Pubitemid 41531394)
102. Knispel HH, Goessl C, Beckmann R (1992) Nitric oxide mediate relaxation in rabbit and human corpus cavernosum smooth muscle. Urol Res 20:253-257
103. Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ, Takizawa H, Cieslinski LB, Barnette MS, Rennard SI (2002) PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 26:694-701 (Pubitemid 34557370)
104. Kreindler JL, Jackson AD, Kemp PA, Bridges RJ, Danahay H (2005) Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. Am J Physiol Lung Cell Mol Physiol 288:L894-902 (Pubitemid 40547916)
105. Kukovetz WR, Holzmann S, Wurm A, Poch G (1979) Evidence for cGMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle. Naunyn-Schmiedebergs Arch Pharmacol 310:129-138 (Pubitemid 10179566)
106. Kumar M, Bhattacharya V (2007) Cilostazol: a new drug in the treatment intermittent claudication. Recent Pat Cardiovasc Drug Discov 2:181-185 (Pubitemid 350200286)
107. Kumar RK, Herbert C, Thomas PS, Wollin L, Beume R, Yang M, Webb DC, Foster PS (2003) Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 307:349-355 (Pubitemid 37151927)
108. Lad PM, Goldberg BJ, Smiley PA, Olson CV (1985) Receptor-specific threshold effects of cyclic AMP are involved in the regulation of enzyme release and superoxide production from human neutrophils. Biochem Biophys Acta 846:286-295 (Pubitemid 16248422)
109. Langendorff O (1895) Untersuchungen am Überlebenden Saugethierherzen. Arch ges Physiol 61:291-332
110. Leclerc O, Lagente V, Planquois JM, Bethelier C, Artola M, Eichholtz T, Bertrand CP, Schmidlin F (2006) Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 27:1102-1109 (Pubitemid 44914292)
111. Lee J-H, Lee D-S, Kim E-K, Oh Y-M, Shim T-S, Kim S-E, Lee Y-S, Lee S-D (2005) Simvastatin inhibits cigarette smoking-induced ephysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 172:987-983
112. Leeman M, Lejeune P, Melot C, Naelje R (1987) Reduction in pulmonary hypertension and in airway resistances by enoximone (NDL 17, 043) in decompensated COPD. Chest 91:662
113. LeJemtel TH, Keung E, Sonnenblick EH, Ribner HS, Matsumoto M, Davis R, Schwartz W, Alousi AA, Davolos D (1979) Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation 59:1098-1104 (Pubitemid 9178545)
114. Liechtenstein ML, Margolis S (1968) Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science 161:982-983
115. Lorenz KL, Wells JN (1982) Potentiation of the effects of sodium nitroprusside and of isoproterenol by selective phosphodiesterase inhibitors. Mol Pharmacol 23:424-430 (Pubitemid 13116867)
116. Lotvall J, Inman M, OByrne P (1998) Measurements of airway hyperresponsiveness: new considerations. Thorax 5:419-424 (Pubitemid 28261338)
117. Macht DI, Ting GC (1921) A study of antispasmodic drugs in the bronchus. J Pharmacol Exp Ther 18:373-398
118. MacPhee CH, Harrison SA, Beavo JA (1986) Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents. Proc Natl Acad Sci 83:6660-6663 (Pubitemid 17174795)
119. Magnus R (1904) Versuche am Überlebenden DÜnndarm von Saugethieren. PflÜgers Arch 102:123-151
120. Marone G, Columbo M, Triggiani M, Cirillo R, Genovese A, Formisano S (1987) Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin. Biochem Pharmacol 36:13-20 (Pubitemid 17227209)
121. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G (2005) Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172:848-853 (Pubitemid 41369068)
122. Martorana PA, Lunghi B, Lucattelli M, de Cunto G, Beume R, Lungarella G (2008) Effect of roflumilast on inflammatory cells in lungs of cigarette smoke-exposed mice. BMC Pulm Med 8:17-26
123. Mata M, Sarriá B, Buenestado A, Cortijo J, Cerdá M, Morcillo EJ (2005) Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 60:144-52 (Pubitemid 40222898)
124. Maurice DH, Haslam RJ (1990) Molecular basis of synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671-681 (Pubitemid 20171502)
125. May CD (1974) History of the introduction of theophylline into the treatment of asthma. Clin Allergy 4:211-217
126. Milara J, Cortijo J, Armengot M, Banuls P, Gabarda E, Morcillo E (2008a) Effect of roflumilast, a PDE4 inhibitor on ciliary beat frequency in human nasal epithelial cells. Eur Respir J Suppl 639s:P3651
127. Milara J, Cortijo J, Mata M, Donet E, Mauricio M, Morcillo EJ (2008b) The PDE4 inhibitor roflumilast N-oxide partly reversed TGFβ1-induced changes in collagen I and E-cadherin expression in human airway epithelial cells. Eur Respir J (Suppl) 639s:P3648, abstract
128. Morley J, Sanjar S, Page CP (1984) Platelet activation as a basis for asthma exacerbation. Lancet 2:1142-1144
129. Murray JL, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349:1498-1504 (Pubitemid 27216360)
130. Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2008). Roflumilast N-oxide inhibits NADPH oxidase expression and activity in human pulmonary artery smooth muscle cells; Proc Br Pharmacol Soc 027P, (abstract).
131. Naline E, Qian Y, Advenier C, Raeburn D, Karlsson J-A (1996) Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle. Br J Pharmacol 118:1939-1944 (Pubitemid 26292561)
132. Nicholson CD, Jackman SA, Wilke R (1989) The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the re-uptake site. Br J Pharmacol 97:889-897 (Pubitemid 19168724)
133. Nicholson CD, Challiss RAJ, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19-27
134. Nielson CP, Vestal RE, RJ S, Heaslip R (1990) Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Alllergy Clin Immunol 86:801-808
135. OConnolly M, Dierdorf D, Greb WH, Mayer M-ER, Wolf D (1988) Efficacy of denbuffylline in patients with multi-infarct dementia. Dru Dev Res 14:195-198 (Pubitemid 19156333)
136. Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong N-S (2004) A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 98:1016-1024 (Pubitemid 40029133)
137. Orange RO, Austen WG, Austen KF (1971) Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. J Exp Med 134:136-148
138. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tendon PK, DeMets DL (1991) Effect of oral milrinone on mortality in severe heart failure. N Engl J Med 3325:1468-1475
139. Pedemonte N, Galietta L (2008). Stimulation of CFTR-dependent chloride secretion by roflumilast. Eur Respir J Suppl 644s:P3672.
140. Persson CG (1985) On the medical history of xanthines and other remedies for asthma: a tribute to HH Salter. Thorax 40:881-886 (Pubitemid 16199119)
141. Pilcher JD (1912) The action of caffein on the mammalian heart. J Pharmacol Exp Med 3:609-624
142. Plant OH (1914) A note of the efficiency of the Knowlton-Starling isolated heart-lung preparation for testing the action of drugs. J Pharmacol Exp Med 5:603-614
143. Poech G, Kukovetz WR (1971) Papaverine -induced inhibition of phosphodiesterase activity in various mammalian tissues. Life sci 10:133-144
144. Polson JB, Krzanowski JJ, Szentivani A (1982) Inhibition of a high cyclic AMP phosphodiesterase and relaxation of canine tacheal smooth muscle. Biochem Pharmacol 21:3403-3406 (Pubitemid 13234500)
145. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen (1993) Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol 264:L458-L464 (Pubitemid 23150827)
146. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H (1994) Identification of PDE isoenzymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 266:L536-L543
147. Rall TW, Sutherland EW (1958) Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem 232:1065-1091
148. Rall TW, West TC (1963) The potentiation of cardiac inotropic responses to norepinephrine by theophylline. J Pharmacol Exp Ther 139:269-274
149. Rau S (2001) Von Coffein zum Furosemid. Entdeckung, Erforschung und Entwicklung der Diuretika im 20. Jahrhundert.
150. Peter Lang, Frankfurt aM Reaburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE, Webber SE, Karlsson J-A (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113:1423-1431 (Pubitemid 24364430)
151. Reeves ML, Leigh PK, England PJ (1987) The identification of a new cyclic nucleotide phosphodiesterase in human and guinea-pig cardiac ventricle. Biochem J 241:535-541
152. Robichaud A, Savoie C, Stamatiou LN, Jolicoeur P, Rasori R, Chan CC (2002) Assessing the potential of PDE4 inhibitors in rats. Br J Pharmacol 135:113-118 (Pubitemid 34102104)
153. Robicsek SA, Krzanovski JJ, Szentivani A, Polson JB (1989) High pressure liquid chromatography of cyclic ncleotide phosphodiesterase from purified human T-lymphocytes. Biochem Biophys Res Comm 163:554-560 (Pubitemid 19227342)
154. Robicsek SA, Blanchard DK, Djeu JY, Krzanowski JJ, Szentivani A, Polson JB (1991) Multiple highaffinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 42:869-877
155. Rosengarten B, Schermuly RT, Voswinkel R, Kohstall MG, Olschewski H, Weissmann N, Seeger W, Kaps M, Grimminger F, Ghofrani HA (2006) Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. Cerebrovasc Dis 21:194-200
156. Rudd MR, Gellert AR, Studdy PR, Geddes DM(1983) Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M&B 22, 948). Br J Dis Chest 77:78-86 (Pubitemid 13183047)
157. Russo LL, Lebel LA, Koe RB (1987) Effects of selected phosphodiesterase (PDE) inhibitors on calcium-independent PDE activity and rolipram binding sites of cerebral cortex. Soc Neurosci Abstr 13:903
158. Salter HH (1860) Asthma. Its pathology and treatment. Churchill, London
159. Sanz MJ, Cortijo J, Taha MA, Cerdá-Nicolás M, Schatton E, Burgbacher B, Klar J, Tenor H, Schudt C, Issekutz AC, Hatzelmann A, Morcillo EJ (2007) Roflumilast inhibits leukocyteendothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 152:481-492 (Pubitemid 47585048)
160. Schade FU, Schudt C (1993) The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol 230:9-14 (Pubitemid 23024974)
161. Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, Seeger W, Schudt C, Wallmarath D (1999) Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 160:1500-1506
162. Schmiechen R, Schneider HH, Wachtel H (1990) Close correlation between behavioural response and binding in vivo for inhibitors of rolipram-sensitive phosphodiesterase. Psychopharmacology 102:17-20 (Pubitemid 20227522)
163. Schneider HH, Schmiechen R, Brezinski M, Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115 (Pubitemid 16023615)
164. Schroeder Wv (1887) Ueber die Wirkung des Coffeins als Diuretikum. Arch Exp Path Pharmacol 22:39-61
165. Schudt C, Winder S, Eltze M, Kilian U, Beume R (1991a) Zardaverine: a cyclic AMP specific PDE III/IV inhibitor. Agents Actions (Suppl) 34:379-402
166. Schudt C, Winder S, Forderkunz S, Hatzelmann A, Ullrich V (1991b) Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn-Schmiedebergs Arch Pharmacol 344:682-690
167. Schudt C, Winder S, Mueller B, Ukena D (1991c) Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem Pharmacol 42:153-161
168. Schudt C, Tenor H, Wendel A, Eltze M, Magnussen H, Rabe KF (1993) Influence of the PDEIII/IV inhibitor B9004-070 on contraction and PDE activities in airway and vascular smooth muscle. Am Rev Respir Dis 147:A183
169. Semmler J, Wachtel H, Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-a production by human mononuclear cells. Int J Immunopharmac 15:409-413 (Pubitemid 23153552)
170. Seybold J, Newton R, Wright L, Finney PA, Suttorp N, Barnes PJ, Adcock IM, Giembycz MA (1998) Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. J Biol Chem 273:20575-20588 (Pubitemid 28377628)
171. Simet SM, Sisson JH, Pavlik JA, Devasure JM, Boyer C, Liu X, Kawasaki S, Sharp JG, Rennard SI, Wyatt TA (2009) Long-term cigarette smoke exposure in a mouse model of ciliated epithelial cell function. Am J Respir Cell Mol Biol 43(6):635-640
172. Souness JE (1996) Characterization of different states of PDE4 by rolipram and RP 73401. In: Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors. Academic, London
173. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman N, Karlsson J-A (1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF generation from human monocytes by interacting with a "low affinity" phosphodiesterase 4 conformer. Br J Pharmacol 118:649-658 (Pubitemid 26180979)
174. Souness JE, Houghton C, Sardar N, Withnall MT (1997) Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer. Br J Pharmacol 121:743-750 (Pubitemid 27260779)
175. Stawiski MA, Rusin LJ, Burns TL, Weinstein GD, Voorhees JJ (1979) Ro 20-1724: an agent that significantly improves psoriatric lesions in double-blind clinical trials. J Invest dermatol 73:261-263 (Pubitemid 10161224)
176. Takeyama K, Jung B, Shim JJ, Burgel PR, Dao-Pick T, Ueki IF, Protin U, Kroschel P, Nadel JA (2001) Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am J Physiol Lung Cell Mol Physiol 280:L165-72
177. Tenor H, Schudt C (1996) Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. In: Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors. Academic, London
178. Tenor H, Hatzelmann A, Wendel A, Schudt C (1995a) Identification of phosphodiesterase IV activity and its cyclic adenosine monophosphate-dependent up-regulation in a human keratinocyte cell line (HACAT). J Invest Dermatol 105:70-74
179. Tenor H, Staniciu L, Schudt C, Hatzelmann A, Wendel A, Djukanovic R, Church MK, Shute JK (1995b) Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 25:616-624
180. Tenor H, Hatzelmann A, Kupferschmidt R, Staniciu L, Djukanovic R, Schudt C, Wendel A, Church MK, Shute JK (1995c) Cyclic nucleotide phosphodiestererase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 25:625-6333
181. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK (1996) Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 118:1727-1735 (Pubitemid 26252668)
182. Tenor H, Burgbacher B, Schudt C, Hatzelmann A (2005) Effects of roflumilast and other PDE4 inhibitors on human CD8+ T-cell functions. Eur Respir J Suppl 26:717s
183. Tenor H, Bundschuh D, Schudt C, Bredenbroker D, Hatzelmann A (2007) Phosphodiesterase 4 inhibitors in the treatment of COPD. In: Stockley RS, Renard SI, Rabe KF, Celli B (eds) Chronic obstructive pulmonary disease. Blackwell, Oxford
184. Thompson WJ, Appleman MM (1971) Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10:311-316
185. Thompson WJ, Ross CP, Pledger WJ, Strada SJ, Banner RL, Hersh EM (1976) Cyclic adenosine 30:50-monophosphate phosphodiesterase: distinct forms in human lymphocytes and monocytes. J Biol Chem 251:4922-4929
186. Thompson WJ, Terasaki WL, Epstein PM, Strada SJ (1979) Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucl Res 10:69-92
187. Thorne JR, Broadley KJ (1994) Adenosine-induced bronchoconstriction in conscious hyperresponsive and sensitized guinea-pigs. Am J Respir Crit Care Med 149:392-399 (Pubitemid 24068986)
188. Thusu KJ, Morin FC, Russell JA, Steinhorn RA (1995) The cGMP phosphodiesterase inhibitor zaprinast enhances the efffect of nitric oxide. Am J Respir Crit Care Med 152:1605-1610
189. Togo S, Liu X, Wang X, Sugiura H, Kamio K, Kawasaki S, Kobayashi T, Ertl RF, Ahn Y, Holz O, Magnussen H, Fredriksson K, Skold CM, Rennard SI (2009) The PDE4 inhibitors roflumilast and rolipran augment PGE2 inhibition of TGFβ1 stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol 296:L959-L969
190. Tomkinson A, Karlsson J-A, Raeburn D (1993) Comparison of the effects of selective inhibitors of phosphodiesterase type III an IV in airway smooth muscle with differing β-adrenoceptor subtypes. Br J Pharmacol 108:57-61 (Pubitemid 23007408)
191. Torphy TJ, Cieslinsky LB (1989) Characterization and selective Inhibition of cyclic nucleotide phosphodiesterase isoenzymes in canine tracheal smooth muscle. Mol Pharmacol 37:206-214
192. Torphy TJ, Undem BJ (1991) Phosphodiesterase inhibitors: new opportunities for treatment of asthma. Thorax 46:512-523
193. Torphy TJ, Burman M, Huang LB, Tucker SS (1988) Inhibition of the low Km cyclic AMP phosphodiesterase in intact canine trachealis by SKF 94863: mechanical and biochemical responses. J Pharmacol Exp Ther 246:843-850
194. Torphy TJ, Zhou HL, Cieslinski LB (1992a) Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulatis cyclic AMP-specific phosphodiesterase activity. J Pharmacol Exp Ther 263:1195-1205 (Pubitemid 23157198)
195. Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, With JR, Livi GP (1992b) Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267:1796-1804
196. Torphy TJ, Undem BJ, Cieslinski LB, Luttmann MA, Reeves ML, Hay DW (1993) Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther 265:1213-1223 (Pubitemid 23321022)
197. Trendelenburg O (1912) Physiologische und pharmakologische Untersuchungen an der isolierten Bronchialmuskulatur. Arch Exp Path Pharmacol 69:79-107
198. Tudor RM, Voelkel NF (2002) The pathobiology of chronic bronchitis and emphysema. In: Voelkel NF, MacNee W (eds) Chronic obstructive lung disease. BC Decker, London
199. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, Torphy TJ (1993) Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cAMP-specific phosphodiesterase inhibitor rolipram. J Pharmacol Exp Ther 266:306-313 (Pubitemid 23315663)
200. Underwood DC, Kotzer CJ, Bochnovicz S, Osborn RR, Luttmann MA, Hay DWP, Torphy TJ (1994) Comparison of Phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 270:250-259 (Pubitemid 24229635)
201. Verghese MW, McConnell RT, Lenhard JM, Hamacher L, Jin C (1995) Regulation of distinct cyclic AMP-specific phosphodiesterase (posphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol 47:1164-1171
202. Virag R, Zwang G, Dermange H, Legman M (1981) Vasculogenic impotence: a review of 92 cases in 54 surgical operations. Vasc Sug 15:9-17 (Pubitemid 11134162)
203. Vogel HG (2002) Drug discovery and evaluation. Springer, Heidelberg
204. Wachtel H (1983) Species differences in behavioural effects of rolipram and other adenosine cyclic 3, 5-monophosphate phosphodiesterase inhibitors. J Neural Transm 56:139-152 (Pubitemid 13134157)
205. Wachtel H, Schneider HH (1986) Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 25:1119-1126 (Pubitemid 16010226)
206. Weidenbach A, Braun C, Schwoebel F, Beume R, Marx D (2008a) Steroid-insensitivity in a shortterm model of cigarette smoke-induced pulmonary inflammation in mice. Am J Respir Crit Care Med (Suppl) A651 (abstract
207. Weidenbach A, Braun C, Schwoebel F, Beume R, Marx D (2008b) Therapeutic effects of various PDE4 inhibitors on cigarette smoke-induced pulmonary neutrophilia in mice. Am J Respir Crit Care Med (Suppl) A651 (abstract
208. Weishaar RE, Cain MH, Bristol JA (1985) A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 28:537-545 (Pubitemid 15098154)
209. Weisshaar RE, Quade M, Boyd D, Schenden J, Marks S, Kaplan HR (1983) The effect of several "new and novel" cardiotonic agents on key subcellular processes involved in the regulation of myocardial contractility: implications for mechanism of action. Drug Dev Res 3:517-534 (Pubitemid 14221034)
210. Wetzel B, Hauel N (1988) New cardiotonic agents -a promising approach for treatment of heart failure. Trends Pharmacol Res 9:166-170
211. Wilkens JH, Neuenkirchen H, Sybrecht GW, Oellerich M (1984) Individualizing theophylline dosage: evaluation of a single-point maintenance dose prediction method. Eur J Clin Pharmacol 26:491-498 (Pubitemid 14149131)
212. Wohlsen A, Wollin L, Marx D, Beume R (2006). Effect of roflumilast and other cAMP elevating agents on airway beat ciliary frequency in proximal and distal airways in rat precision cut lung slices. Fifth international multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5), June 28-30, Birmingham, UK: Poster P25.